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Lung cancer is the leading cause of cancer-related death in the
United States. Despite the availability of several cytotoxic and a few
molecularly targeted agents, the outlook for patients with advanced
non-small cell lung cancer continues to be dismal. Novel approaches
are desperately needed. The insulin-like growth factor (IGF) path-
way plays an important role in a number of human malignancies
contributing to unregulated cell proliferation. The IGF pathway has
several targets for therapeutic intervention. Preclinical studies of
IGF inhibitors have demonstrated synergism when combined with
chemotherapy agents and radiation. Clinical studies are currently
ongoing to investigate the safety and efficacy of IGF inhibitors in
combination with chemotherapy agents. In this review, we discuss
the biology of the IGF pathway and various potential targets for
therapy.
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Insulin-like growth factor (IGF) is a polypeptide growthfactor with functional homology to insulin.1 IGF has a wide
range of metabolic and developmental functions, including
embryogenesis and postnatal organogenesis.2 The IGF sig-
naling pathway plays a critical role in regulating cell prolif-
eration and apoptosis. In this review, we discuss the rationale
for targeting the IGF pathway in the treatment of non-small
cell lung cancer (NSCLC) (Figure 1).
THE IGF PATHWAY
The IGF system involves complex regulatory network
comprising IGF-1 and IGF-2 ligands, six specific high-affin-
ity binding proteins (IGFBP-1 to IGFBP-6) and IGFBP pro-
teases (IGFBP-prs), and IGF-1 and IGF-2 cell surface recep-
tors (IGF-1R and IGF-2R).3 The half-life and bioavailability
of IGF-1 and IGF-2 in circulation varies depending on
the affinity and specificity of the IGFBPs in the serum.4
IGFBP-3, the most critical of the binding protein, binds to
70% to 80% of the IGF-1.5 Various matrix metalloproteinases
(MMPS), often secreted by the tumors, exert proteolytic
action on IGFBPs, particularly IGFBP-3, thus increasing the
bioavailability of IGFs for receptor-mediated action.6–9 In
addition, IGFBP-3 seems to have a non-IGF mediated anti-
proliferative and pro-apoptotic action resulting from its asso-
ciation with cell surface proteins or receptors.10
Most of the actions of IGF-1 and IGF-2 are mediated by
high-affinity ligand binding to IGF-1R, although recent evi-
dence suggests that actions of IGF-2 are also mediated
through the high-affinity binding with an insulin receptor (IR)
isoform-insulin receptor exon 11 isoform (IR-A).11 Upon
binding of the IGFs to IGF-1R, the receptor’s intrinsic ty-
rosine kinase is activated, resulting in the phosphorylation of
the insulin receptor substrates (IRSs).11–13 The tyrosine-phos-
phorylated IRS activates phosphatidylinositol-3kinase
(PI3K), which catalyzes the conversion of phosphatidylino-
sitol biphosphate (PIP2) to phosphatidylinositol triphosphate
(PIP3). V-Akt murine thymoma viral oncogene homolog
(Akt) is activated by PIP3. Activated Akt results in a cascade
of phosphorylation events in the cytosol, resulting in inacti-
vation of key proteins (Bcl-2 antagonist of cell death, caspase
9, and forkhead transcription factor family) involved in apo-
ptosis.14 The activation of IGF-1R also modulates the volt-
age-gated calcium channels, causing transient increase in the
intracellular Ca2
 level and thereby regulating the nuclear
transcription factor, cAMP response element-binding protein
(CREB). IGF-2 accentuates the survival and proliferation of
lung cancer cells by increasing phosphorylation of CREB via
the erk5 pathway.15,16
The insulin growth factor-II receptor (IGF2R) lacks
signal transduction capability, and its main role is to act as a
sink for IGF II and make less IGF II available for binding
with IGF-1R.17
THE IGF PATHWAY IN LUNG CANCER
Autocrine production of IGF by the tumor cells and
high levels of IGF 1 have been reported in the lung tumor
tissue.18,19 Human lung cancer cells also seem to have a
higher expression of IGF-2 compared with normal cells and
is associated with poor prognosis.16,20 IGF-2 is overexpressed
in both the small cell lung cancer (SCLC) and NSCLC cell
lines.21 Increased expression of IGF-2 in lung cancer results
from aberrant regulation of the genomic imprinting mecha-
nism of IGF-2 and mesoderm-specific transcript genes.22
Genetic aberrations of the M6P/IGF2R locus have been
reported in lung cancer cell lines.23–25 More studies of lung
tumor tissue are needed to further elucidate the role of
M6P/IGF2R gene in the onset and progression of lung cancer.
The IGF-1R seem to be overexpressed in both NSCLC
and SCLC.26–28 Increased metastatic activity was reported in
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mice after intrasplenic injection of lung cancer cell lines
transfected with IGF-1R receptors.29
Decreased expression of IGFBP-3 is also associated
with a higher risk of lung cancer indirectly by increasing the
bioavailability of IGF ligands.30–32 IGFBP-3 expression lev-
els are low in one of the four SCLC cell lines and all four of
the NSCLC cell lines studied.33 Hypermethylation of the
IGFBP-3 promoter is common (60%) in NSCLC tissue and
is strongly associated with poor prognosis in patients with
stage 1 NSCLC (5-year overall survival of patients with
IGFBP-3 versus patients without IGFBP-3 hypermethylation
is 38.9% versus 64.0%).30
A recently published report on a genome wide scan of
1529 patients with lung cancer and 2707 controls in the
United Kingdom reported strong evidence that low-pen-
etrance alleles of genes involved in the growth hormone IGF
axis are associated with lung cancer susceptibility.34 In a case
control study of 204 consecutive patients with primary lung
cancer and 218 age-, sex-, race-, and smoking status-matched
control subjects, a higher plasma levels of IGF-1 was asso-
ciated with an increased risk of lung cancer (OR 2.06; CI
95%).35 IGF-mediated signaling mechanisms are essential for
the proliferation, survival, and metastases of lung cancer
cells. Inhibition of IGF activity is associated with decreased
tumor growth in vitro.36–38 There are several ongoing studies
exploring the possible therapeutic role of targeting IGF reg-
ulation.
THE IGF PATHWAY AS A THERAPEUTIC
TARGET
The IGF pathway presents several targets of interest for
molecular therapeutics. The possible therapeutic strategies
targeting IGF axis-targeted therapies are growth hormone-
releasing hormone antagonists, somatostatin analogs, growth
hormone (GH) receptor antagonists, IGF-1R antibodies, an-
tibodies directed against IGF ligands, and increasing levels of
IGFBP-3.
Clinical trials using somatostatin and other GH receptor
antagonists failed to show significant benefit, perhaps be-
cause of inadequate reduction in the levels of IGFs. The
effect of growth hormone in regulating IGFs of tumor origin
is possibly limited; thus, strategies targeting GH may not
offer a significant antitumor action.
In vitro studies demonstrated that inhibition of the
IGF-1R signaling pathway in human NCLC cells A549 has
tumor-inhibiting action and enhances sensitivity to apoptosis-
inducing agents.39,40 Inhibition of IGF-1 signaling using
IGF-1R kinase inhibitor NVP-ADW742 has a synergistic
increase in the sensitivity of SCLC cell lines to etoposide and
FIGURE 1. The insulin-like growth factor pathway.
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carboplatin.41 In vitro studies of dual inhibition of IGF-1R
(AG 1024) and c-kit activity (AG 1296) produce synergistic
activity in SCLC cell lines.42
In vitro studies on six NSCLC cell lines’ blocking of
IGF-1R function with anti-IGF-1R monoclonal antibodies
potentiated the cytotoxic effects of radiation in a synergistic
fashion in one cell line, in an additive fashion in four cell
lines, and in a sub-additive fashion in one cell line.43 Com-
plete inhibition of tumor growth has been observed when
anti-IGF-1R antibody (h7C10) is combined with vinorelbine
or an anti-epidermal growth factor receptor antibody in ani-
mal models.40 Clinical trials are currently ongoing to assess
the safety and efficacy of human monoclonal antibodies
specific for IGF-1R, such as CP-751,871 in advanced
NSCLC.
Human monoclonal antibodies specific for IGF-2 have
been developed (IgG1 m610), and these antibodies showed
good inhibitory activity in in vitro models. IGF-1R is widely
expressed, has a broad range of physiological actions, and
bears a high homology to the insulin receptor; hence, the use
of IGF-1R antibodies could possibly result in more toxicities
compared with the use of antibodies directed against IGF
ligands.44
Transfection of IGFBP-3 into lung cancer cell lines
seemed to have profound antitumor effect to the tumor cells
in vitro and in vivo.45,46 Similar results have been found using
recombinant human IGFBP-3 in lung carcinoma models us-
ing 3LL Lewis lung carcinoma allograft, suggesting a poten-
tial therapeutic role of IGFBP-3.47,48 Thus, IGBP-3 may also
represent a potential target.
In summary, the IGF pathway seems to play a critical
role in human neoplasia in general and in lung cancer in
particular. Clinical trials with IGF inhibitors just begun in
NSCLC hopefully will show promising results.
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